Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266367 | 0.91 | EPHX1 (0.49) | CYP1A2USP2TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL5197128 | 0.90 | EPHX1 (0.56) | CYP1A2SMN1; SMN2EPHX1SIGMAR1EPHX2 | |
| SCHEMBL13114610 | 0.90 | SMYD3 (0.44) | CYP1A2USP2TSHRSMYD3KMT2A | |
| SCHEMBL21695552 | 0.88 | SMN1; SMN2 (0.47) | CYP1A2USP2TSHRSMYD3KMT2A | |
| SCHEMBL13850703 | 0.86 | CYP1A2 (0.45) | CYP1A2USP2TSHRSMYD3KMT2A | |
| SCHEMBL13114605 | 0.86 | SMYD3 (0.45) | CYP1A2USP2TSHRSMYD3KMT2A | |
| SCHEMBL21730449 | 0.86 | EPHX1 (0.53) | CYP1A2USP2TSHRSMYD3KMT2A | |
| SCHEMBL18949684 | 0.85 | KDM4E (0.44) | CYP1A2USP2TSHRSIGMAR1EPHX2 | |
| SCHEMBL21695556 | 0.81 | SMN1; SMN2 (0.53) | CYP1A2SMN1; SMN2EPHX1SIGMAR1KDM4E | |
| SCHEMBL10283928 | 0.80 | SMYD3 (0.50) | SMYD3KMT2AL3MBTL1EPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-RE47396-E1 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9920041-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9611260-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9566283-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-8324200-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885USP2 1382/4885TSHR 3902/4885 |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CYP1A2 2611/4885USP2 1382/4885TSHR 3902/4885 |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2264/4885USP2 1340/4885TSHR 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.